Dr. Seedor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
925 Chestnut St
Ste 320A
Philadelphia, PA 19107Phone+1 215-955-8874Fax+1 215-503-2715
Summary
- I am a medical oncologist specializing in cutaneous and ocular melanoma as well as non-melanoma skin cancers. I completed my medical school and residency training at Jefferson, and then completed my hematology/oncology training at Fox Chase Cancer Center/Temple University Hospital.
Education & Training
- Temple University Hospital/Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2021
- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2015 - 2018
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2015
Certifications & Licensure
- DE State Medical License Current
- NJ State Medical License 2022 - 2025
- PA State Medical License 2015 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 41 citationsAdjuvant Sunitinib in High-Risk Patients with Uveal Melanoma: Comparison with Institutional ControlsMatias E. Valsecchi, Marlana Orloff, Rino Sato, Inna Chervoneva, Carol L. Shields
Ophthalmology. 2017-09-01 - 21 citationsGenetic Landscape and Emerging Therapies in Uveal Melanoma.Rino S. Seedor, Marlana Orloff, Takami Sato
Cancers. 2021-11-02 - 6 citationsReview of bi-specific therapies in uveal melanoma.Marlana Orloff, Rino Seedor, Takami Sato
Cancer Gene Therapy. 2022-12-01
Journal Articles
- Treatment of Metastatic Melanoma in the ElderlyRino S. Seedor and Marlana Orloff, Current Oncology Reports, 3/22/2022
- Case Report: Cytarabine-Induced Pericarditis and Pericardial EffusionSato R., and Park, R., The Thomas Jefferson Medicine Forum, 2017
- Fatal Rituximab-Induced Nonspecific Interstitial Pneumonia: Case Report and Review of the LiteratureSato, R., Molligan J., and Gaballa, S., The Thomas Jefferson Medicine Forum, 2017
Abstracts/Posters
- The prevalence of hereditary pancreatitis mutations in families with pancreatic cancer.Seedor, R. S., Savage, M. J., Iqbal, W., Arora, S., Rainey, K., Forman, A., Lincoln, S., Garcia, J., Truty, R., Esplin, E. D., Handorf, E. A., and Hall, M. J., 2019 ASCO Annual Meeting.
- Clinical Trial in Progress: Phase II trial of defactinib (VS-6063) combined with VS-6766 (CH5126766) in patients with metastatic uveal melanoma.Seedor, R. S., Orloff, M., Gutkind, J. S., Aplin, A., Terai, M., Sharpe-Mills, E., Klose, H., Mastrangelo, M. J., and Sato, T., 2021 Virtual ASCO Annual Meeting, 6/4/2021
- Prospective study comparing self-administered geriatric assessment to provider’s routine clinical assessment of older patients with metastatic breast cancer treated at...Seedor, R. S., Meeker, C. R., Lewis, B., Handorf, E. A., Filchner, K. A., Winn, J., Goldstein, L. J., and Dotan, E., 2020 Virtual ASCO Annual Meeting, 5/29/2020
- Join now to see all
Other
- Germline Testing in Biliary Tract CancersSeedor, R.S., and Hall, M., ASCO Daily News
https://dailynews.ascopubs.org/do/10.1200/ADN.19.190399/full/.
9/5/2019
Press Mentions
- Metastatic Uveal Melanoma: New Drugs in Pipeline, but Prognoses Remain GrimDecember 14th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: